REXN

MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced Douglas J. Swirsky has been appointed as the Company's Chief Financial Officer, effective immediately. Mr. Swirsky is a seasoned financial leader with over two decades of experience in the healthcare sector, including as a public company executive at Nasdaq-listed organizations.   "We are excited to welcome Douglas to MaxCyte where he brings exceptional financial, strategic, and operational experien

ROCKVILLE, Md., March 27, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced Douglas J. Swirsky has been appointed as the Company's Chief Financial Officer, effective immediately. Mr. Swirsky is a seasoned financial leader with over two decades of experience in the healthcare sector, including as a public company executive at Nasdaq-listed organizations. "We are excited to welcome Douglas to MaxCyte where he brings exceptio

ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that the merger transaction between Rexahn and Ocuphire Pharma, Inc. is expected to be effective shortly after 4:00 pm (EST) today, Thursday, November 5, 2020. As previously announced, Rexahn’s stockholders voted to approve all proposals required to complete the merger transaction. In connection with these approvals, the Board of Directors of Rexahn has approved a reverse stock split of Rexahn’s common stock at a ratio of one share for every 4 shares outstanding, which is expected to become effective immediately prior to the effectiveness of the merger.   Immediately fo

ROCKVILLE, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that at its special meeting of stockholders held on November 2, 2020, Rexahn’s stockholders approved all of the proposals presented, including: (i) the issuance of shares of Rexahn common stock pursuant to the Agreement and Plan of Merger and Reorganization, dated June 17, 2020, as amended, by and among Rexahn, Razor Merger Sub, Inc. and Ocuphire Pharma, Inc. (“Ocuphire”) and the change of control of Rexahn resulting from the merger; (ii) a reverse stock split of Rexahn common stock, at a ratio of one new share for every 3 to 5 shares outstanding, with such final ratio to

NEW YORK, Oct. 15, 2020 /PRNewswire/ --  If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY  10036(212) 682-3025(888) 593-4771[email protected] Eidos Therapeutics, Inc. (NASDAQ: EIDX) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Eidos Therapeutics, Inc. (NASDAQ: EIDX) in connection with the proposed interested-party acquisition of the company by BridgeBio Pharma, Inc., pursuant to which BridgeBio will acquire